Search

Tabelecleucel (Pierre Fabre Laboratories and Atara Biotherapeutics) for Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease

An allogenic T cell immunotherapy proposed for treatment of relapsed or refractory Epstein-Barr virus-positive posttransplant lymphoproliferative disease.

Complete this form to request the full report